HOW AND WHERE TO BUY GEMIFLOXACIN MESYLATE (FACTIVE) 320 MG TABLETS OR CAPSULES ONLINE:
FACTIVE (GEMIFLOXACIN MESYLATE) TABLETS: PRECAUTIONS
Prescribing Gemifloxacin Mesylate (Factive) pills in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
In clinical studies, rash occurred more often with Factive than with therapy with comparator agents (2.7% vs. 0.6%). Increasing incidence of rash was associated with younger age (especially below 40), female gender, use of hormone replacement therapy and longer durations of therapy. Urticarial reactions, some of which were not classified as rash, were more common in Factive (Gemifloxacin) patients than in comparator patients (0.6% vs. 0.2%). Factive should be discontinued in patients developing a rash or urticaria while on treatment.
The most common form of rash associated with Gemifloxacin (Factive) was described as maculopapular and mild to moderate in severity. Eighty percent of rashes resolved within 14 days. Approximately 10% of the rashes (0.5% of all patients) were described as of severe intensity and approximately 10% of those with rash were treated with systemic steroids. There were no documented cases in the clinical trials of more serious skin reactions known to be associated with significant morbidity or mortality.
Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, "V" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with use of quinolones after sun or UV light exposure. Therefore excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if phototoxicity occurs.
Liver enzyme elevations (increased ALT and/or AST) occurred at similar rates in patients receiving Factive 320 mg daily relative to comparator antimicrobial agents (ciprofloxacin, levofloxacin, clarithromycin / cefuroxime axetil, amoxicillin / clavulanate potassium, and ofloxacin). In patients who received gemifloxacin at doses of 480 mg per day or greater there was an increased incidence of elevations in liver enzymes.
There were no clinical symptoms associated with these liver enzyme elevations. The liver enzyme elevations resolved following cessation of therapy. The recommended dose of Factive (Gemifloxacin Mesylate) 320 mg daily should not be exceeded and the recommended length of therapy should not be exceeded.
Alteration of the dosage regimen is necessary for patients with impairment of renal function (creatinine clearance <= 40 mL/min).
Adequate hydration of patients receiving Factive should be maintained to prevent the formation of a highly concentrated urine.
Order Factive (Gemifloxacin Mesylate) Online
Factive prescribing information